Theravance Biopharma TBPH Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $114.54M+8.2% | $105.9M+261% | $29.34M+125% | $13.03M+122% | -$58.33M-3.4% | ||
| $1.59M-2.0% | $1.63M-1.4% | $1.65M-1.4% | $1.67M-1.1% | $1.69M-1.1% | ||
| $18.1M-2.0% | $18.48M-6.8% | $19.82M-1.9% | $20.21M-4.0% | $21.04M-1.6% | ||
| —— | —— | —— | $245.02M+653% | $32.53M+382% | ||
| -$83.91M+20.7% | -$105.87M-17.4% | -$90.19M-1,129% | -$7.34M— | —— | ||
| -$7.97M-145% | -$3.25M-53.1% | -$2.12M-1.3% | -$2.09M-28.1% | -$1.64M+34.5% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Theravance Biopharma generate?
- Theravance Biopharma (TBPH) generated $323.5M in operating cash flow over the trailing twelve months.
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
